Nuestra directiva impulsa activamente la organización para ir más allá en salud

A qualified physicist, Britta Fünfstück has led the HARTMANN GROUP as CEO since January 1, 2019. She is responsible for Corporate Strategy and the core segment Infection Management, covering the Risk Prevention and Disinfection divisions. Furthermore, Britta Fünfstück is in charge of the German domestic market, Digital Business, Human Resources, Corporate Communications, Quality, Compliance and the subsidiary Kneipp. Britta Fünfstück also oversees Operations Management for Disinfection, Risk Prevention and Global Technology Services.

A biomedical engineer by training, François Georgelin has been a member of the Management Board since January 1, 2020. In this function, he is responsible for the core segment Wound Management, the pharmacy and e-business distribution channels and Regulatory Affairs. Furthermore, he manages the market activities in the USA, France, as well as Eastern and Northern Europe. He is also responsible for the subsidiary KOB.

Stefan Grote holds a degree in Business Administration and has been a member of the Management Board since April 1, 2021. In this function, he oversees the core segment Incontinence Management and is responsible for the areas of Procurement, Supply Chain Management and Real Estate Management & Business Services. In addition, he is responsible for the markets in Western and Southern Europe, Africa, the Middle East, Asia-Pacific, Australia and South America.

A qualified economist, Stefan Müller has been a member of the Management Board and Chief Financial Officer since July 1, 2020. In this function, he is responsible for the areas of Finance, Controlling, Strategic Pricing, CorporateLegal, Mergers & Acquisitions, Investor Relations, Internal Audit, Risk Management, IT and Product Lifecycle Management. In addition, he oversees IVF-HARTMANN (Switzerland) as well as the subsidiary CMC.